Selmi, Abderraouf
Vascotto, Fulvia
Kautz-Neu, Kordula
Türeci, Özlem
Sahin, Ugur
von Stebut, Esther
Diken, Mustafa
Kreiter, Sebastian
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (CI3 excellence cluster programm)
Deutsche Forschungsgemeinschaft (TR156, A03)
Article History
Received: 17 March 2016
Accepted: 8 July 2016
First Online: 15 July 2016
Compliance with ethical standards
:
: Ugur Sahin is a stock owner and management board member of BioNTech AG (Mainz, Germany). Mustafa Diken and Sebastian Kreiter are working as advisors for BioNTech RNA Pharmaceuticals GmbH. All other authors have no potential conflict of interest.
Free to read: This content has been made available to all.